Sign inJoin waitlistJoin the waitlist

Laura Metrock

Program Director, Neuro-Oncoloy Fellowship Program · University of Alabama Hospital

Credentials: · · ·

History

Neuro-oncoloy Fellowship · University of Alabama Hospital
Present
University of Alabama Hospital
Present

Pediatric Hematology/Oncology
Emory University School of Medicine
2014–2017
Pediatrics
Emory University
2011–2014
Medical College of Georgia
2006–2010

Research

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Journal of Clinical Oncology · 2025 · 90 citations
Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition
Acta Neuropathologica · 2020 · 81 citations
An Update on Neurofibromatosis Type 1-Associated Gliomas
Review · Cancers · 2020 · 69 citations

AF
Andrea Franson
3 papers
Nicholas Whipple
3 papers
Reuben Antony
3 papers
Amar Gajjar
2 papers
AM
Anita Mahajan
2 papers
Anthony Wang
2 papers
Ashley Plant-Fox
2 papers
Bonnie Cole
2 papers
Daniel Bowers
2 papers
Daniel Landi
2 papers
Duncan Stearns
2 papers
FK
Frank Keller
2 papers

Clinical trials

Digoxin Medulloblastoma Study
Principal investigator · Recruiting · Phase 2
H. Lee Moffitt Cancer Center and Research Institute
2026–2027
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2030
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
Sub-investigator · Recruiting · Phase 2
University of Alabama at Birmingham
2026–2032
Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas
Sub-investigator · Recruiting · Phase 1
Girish Dhall, MD
2026–2034